Genomic Valley Biotech has secured regulatory approval to extend the deadline for holding its Annual General Meeting (AGM) for FY26. The Registrar of Companies (ROC), Haryana granted a three-month extension, pushing the new deadline to December 31, 2026.

The original statutory deadline for the AGM was September 30, 2026, as mandated under Section 96 of the Companies Act, 2013. The company applied for the extension on August 26, 2026, citing health reasons of the promoter as the primary ground for delay.

Regulatory Approval Details

The ROC approved the request vide its letter dated August 30, 2026, under Section 96(1) of the Companies Act, 2013. The order explicitly grants an extension of three months but advises the company to ensure strict compliance with statutory provisions in the future.

The company informed the BSE Limited of this development on August 31, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Yogesh Agrawal, Managing Director, signed the intimation letter.

What the Numbers Show

The reliance on promoter health as the sole justification for delaying a statutory corporate governance milestone highlights potential concentration risk in decision-making authority. While the extension resolves the immediate compliance breach, the ROC’s advisory note suggests heightened scrutiny may be applied to future filings from the entity. No financial performance data was disclosed in this filing.

Genomic Valley Biotech Limited returned to profitability in the financial year ended March 31, 2026, posting a net profit of ₹3,03,041 compared to a net loss of ₹35,60,932 in the previous year. The turnaround was driven by a significant reduction in total expenses, which fell to ₹22,74,590 in FY26 from ₹40,69,678 in FY25, despite a decline in revenue from operations to ₹26,75,000 from ₹84,39,394. The company recorded a basic earnings per share (EPS) of ₹0.10 for the year, against a negative EPS of ₹1.17 in FY25.

For the quarter ended March 31, 2026, the company reported a net loss of ₹81,745 on revenue from operations of ₹3,75,000. The loss before tax for the quarter stood at ₹15,624, with total expenses amounting to ₹3,59,376. In comparison, the quarter ended March 31, 2025, saw a net loss of ₹8,34,895 on total revenue of ₹26,35,770.

Financial Performance

The reduction in expenses was primarily due to lower employee benefits costs, which decreased to ₹10,59,000 in FY26 from ₹12,08,645 in the prior year. However, depreciation and amortization expense increased to ₹37,064 from ₹25,414, and other expenses rose to ₹11,78,525 from ₹8,21,824. The tax expense for the quarter ended March 31, 2026, included a current tax of ₹1,00,000 and a deferred tax adjustment of -₹2,631.

Financial Position

The company's total assets as of March 31, 2026, stood at ₹4,24,95,674, slightly lower than ₹4,35,65,624 in the previous year. Total equity increased to ₹3,92,84,574 from ₹3,89,81,533. Trade receivables rose to ₹2,31,77,445 from ₹2,21,44,945, while cash and cash equivalents decreased sharply to ₹42,936 from ₹2,28,976.

Board Appointments

The Board of Directors approved the appointment of Mr. Navjyoti Kumar Jha as the Internal Auditor for the financial year 2026-27. Mr. Jha holds a Bachelor of Commerce degree and brings 26 years of experience to the role. He is not related to any director of the company. The statutory auditors, M/s ANDROS & Co. Chartered Accountants, issued an unmodified opinion on the audited standalone financial results.